Article
Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease.
BMC medicine - 8 Nov 2012
Bruera Gemma, Cannita Katia, Di Giacomo Daniela, Lamy Aude, Troncone Giancarlo, Dal Mas Antonella, Coletti Gino, Frébourg Thierry, Sabourin Jean Christophe, Tosi Mario, Ficorella Corrado, Ricevuto Enrico
Abstract excerpt
BACKGROUND: Bevacizumab (BEV) plus triplet chemotherapy can increase efficacy of first-line treatment of metastatic colorectal cancer (MCRC), particularly integrated with secondary liver surgery in liver-limited (L-L) patients. The prognostic value of the KRAS genotype in L-L and other or multiple metastatic (O/MM) MCRC patients treated with the FIr-B/FOx regimen was retrospectively evaluated. METHODS: Tumoral...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.